Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Immunicum: MERECA data maturing in a positive direction

2020-02-07

10:22

KP

Klas Palin

Yesterday’s ASCO SITC presentation provided a 24 months follow-up of the MERECA trial, and our overall impression of the new data is positive, supporting the benefit of adding ilixadencel to sunitinib. With growing confidence in ilixadencel, we are now raising our base case to SEK 17 (14). However, the share price is lower in early trading, suggesting high expectations from investors.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers